Advertisement

Evaluation of Dalbavancin in Vancomycin Allergic Patients: A Case Series

      Abstract

      Purpose

      There is a paucity of data regarding dalbavancin use in patients with a vancomycin allergy because of potential cross-reactivity between the 2 glycopeptide antibiotics.

      Methods

      A retrospective medical record review was performed between February 2016 and February 2021 in patients with a listed vancomycin allergy who received dalbavancin as an outpatient infusion and had a listed vancomycin allergy in the electronic health record.

      Findings

      There were 559 unique patients during the study period who received dalbavancin as an outpatient infusion, 10 of whom had a documented vancomycin allergy in the electronic health record. Four of the 10 patients had a history of a type I IgE-mediated reaction to vancomycin, 1 patient reported delayed rash, 2 patients reported a vancomycin infusion reaction, 2 patients reported acute kidney injury, and 1 patient reported intolerance with general malaise. All 10 patients received at least 1 dose of dalbavancin with no reported adverse events.

      Implications

      This case series displays that all patients who received dalbavancin tolerated the infusion well with no adverse events reported. Dalbavancin may be a viable option for patients with a listed vancomycin allergy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Dalvance (dalbavancin) [prescribing information].
        Allergan USA, Inc., Madison, NJ2021 (Accessed 22 Apr 2022)
        • Gatti M
        • Andreoni M
        • Pea F
        • Viale P.
        Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
        Drug Des Devel Ther. 2021; 15: 3349-3378
        • Bambeke FV.
        Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
        Curr Opin Pharmacol. 2004; 4: 471-478
        • Ishizuka KT
        • Tran TK
        • Ayars AG
        • Chau AS
        • Chan JD.
        Graded dalbavancin challenge in a patient with severe vancomycin hypersensitivity reaction.
        Clin Infect Dis. 2020; 70: 1230-1232
        • Nakkam N
        • Gibson A
        • Mouhtouris E
        • et al.
        Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype.
        J Allergy Clin Immunol. 2021; 147: 403-405
        • Rybak MJ
        • Le J
        • Lodise TP
        • et al.
        Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
        Clin Infect Dis. 2020; 71: 1361-1364
        • Bland CM
        • Crosby CM
        • Orvin DL
        • Smith SE
        • Jones BM.
        Transitioning from guideline approval to practical implementation of AUC-based monitoring of vancomycin.
        Am J Health Syst Pharm. 2021; 78: 1270-1272
      2. Orbactiv (oritavancin) [prescribing information].
        Melinta Therapeutics, Inc., 2019 (Accessed April 22, 2022)
        • Dunne MW
        • Puttagunta S
        • Giordano P
        • Krievins D
        • Zelasky M
        • Baldassarre J.
        A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection.
        Clin Infect Dis. 2016; 62: 545-551
        • Nakkam N
        • Gibson A
        • Mouhtouris E
        • Kovinse K
        • et al.
        Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.
        J Allergy Clin Immunol. 2021; 147: 403-405
        • Solensky R
        • Khan DA
        • Bernstein IL
        • et al.
        Drug allergy: an updated practice parameter.
        Ann Allergy Asthma Immunol. 2010; 105: 259-273
        • Jones BM
        • Hersey R
        • Taylor C
        • Bland CM.
        Evaluation of dalbavancin on length of stay in acute bacterial skin and structure infections.
        J Am Coll Clin Pharm. 2019; 2: 477-481
        • Pizzuti AG
        • Murray EY
        • Wagner JL
        • Gaul GA
        • Bland CM
        • Jones BM.
        Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients.
        Infect Dis Ther. 2020; 9: 1043-1053
        • Antosz K
        • Al-Hasan MN
        • Lu ZK
        • et al.
        Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care.
        Pharmacy. 2021; 10: 1